Monte Rosa Therapeutics, Inc. (GLUE) Form SCHEDULE 13D/A — Jul 6, 2026

$GLUEForm SCHEDULE 13D/AFiled Jul 6, 2026, 5:51 PM ET0001072613-26-000558Original filing

New Enterprise Associates 17, L.P. and associated entities executed a joint filing agreement to report their collective beneficial ownership of Monte Rosa Therapeutics, Inc. via Schedule 13D. The filing discloses that NEA Investment Holdings CF, LLC sold 11,830 shares of the company's common stock in open market transactions on July 2, 2026.

Key figures

Shares sold: 11,830
Price range max: $24.68
Price range min: $23.70
Transaction date: 2026-07-02
Weighted average price: $24.18096

AI analysis

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $49/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.